Vaccine-preventable pediatric postmeningitic sensorineural hearing loss in southern India

Otolaryngology - Head and Neck Surgery

Volumn 130, Issue 3, 2004, Pages 339-343

  Cherukupally, Shilpa Reddy ^a,b   Eavey, Roland ^a,b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFOTAXIME; DEXAMETHASONE; ETHAMBUTOL; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; ISONIAZID; PNEUMOCOCCUS VACCINE; PYRAZINAMIDE; RIFAMPICIN;

ARTICLE; BACTERIAL MENINGITIS; CEREBROSPINAL FLUID CULTURE; CHILD; DEVELOPING COUNTRY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOPROPHYLAXIS; INDIA; INFANT; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PEDIATRIC HOSPITAL; PERCEPTION DEAFNESS; PILOT STUDY; POPULATION; PREVALENCE; PROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE; TUBERCULOUS MENINGITIS; VACCINATION;

EID: 1842477406     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2003.11.017     Document Type: Article

References (17)

1. Richardson MP, Reid A, Tarlow MJ, et al. Hearing loss during bacterial meningitis. Arch Dis Child 1997;76: 134-8.
2. Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 1984;311:869-74.
3. Rasmussen N, Johnson NJ, Bohr VA. Otologic sequelae after pneumococcal meningitis: a survey of 164 consecutive cases with a follow-up of 94 survivors. Laryngoscope 1991;101:876-82.
4. Woolley AL, Kirk KA, Neumann AM, et al. Risk factors for hearing loss from meningitis in children. Arch Otolaryngol Head Neck Surg 1999;125:509-14.
5. Van Beneden CA, Whitney CG, Levine OS. Preventing pneumococcal disease among infants and young children. MMWR Morb Mortal Wkly Rep 2000;49:1-38.
6. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-9.
7. Barnett ED, Pelton SI, Cabral HJ, et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis 1999;29:191-2.
8. Ray GT, Butler JC, Black SB, et al. Observed costs and health care use of children in a randomized controlled trial of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2002;21:361-5.
9. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM 197 in United States infants. Pediatrics 1998;101:604-11.
10. World Health Organization (WHO). WHO report of the technical review group meeting, Global Program for Vaccines and Immunizations. Vaccine Research and Development. Geneva, Switzerland: WHO; 1998.
11. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000;283: 440-1.
12. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the united states in 1995. N Engl J Med 1997;337:970-6.
13. Arditi M, Mason EO, Bradley JS, et al. Three year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998;102:1087-97.
14. Fortnum HM. Hearing impairment after bacterial meningitis: a review. Arch Dis Child 1992;67:1128-33.
15. Thilothammal N, Krishnamurthy PV, Banu K, et al. Tuberculous meningitis in children: clinical profile, mortality, and morbidity of bacteriologically confirmed cases. Indian Pediatr 1995;32:641-7.
16. Chinchankar N, Mane M, Bhave S, et al. Diagnosis and outcome of acute bacterial meningitis in early childhood. Indian Pediatr 2002;39:914-21.
17. Singh K, Mann SB, Gupta AK, et al. Auditory profile in children recovering from bacterial meningitis. Indian J Pediatr 1996;63:210-6.